title: A direct injection high-throughput liquid chromatography tandem mass spectrometry method for the determination of a new orally active alphavbeta3 antagonist in human urine and dialysate.
abstract: A generic high-throughput liquid chromatography (HTLC) tandem mass spectrometry (MS/MS) assay for the determination of compound I in human urine and dialysate (hemodialysis) was developed and validated. By using the HTLC on-line extraction technique, sample pretreatment was not necessary. The sample was directly injected onto a narrow bore large particle size extraction column (50 x 1.0 mm, 60 microm) where the sample matrix was rapidly washed away using a high flow rate (5 mL/min) aqueous mobile phase while analytes were retained. The analytes were subsequently eluted from the extraction column onto an analytical column using an organic-enriched mobile phase prior to mass spectrometric detection. The analytes were then eluted from the analytical column to the mass spectrometer for the determination. The linear dynamic range was 2.0-6000 ng/mL for the urine assay and 0.1-300 ng/mL for the dialysate assay. Intraday accuracy and precision were evaluated by analyzing five replicates of calibration standards at all concentrations used to construct the standard curve. For the urine assay, the precision (RSD%, n=5) ranged from 1.9 to 8.0% and the accuracy ranged from 87.8 to 105.2% of nominal value. For the dialysate assay, the precision (RSD%, n=5) ranged from 1.1 to 10.0% and the accuracy from 94.5 to 105.2% of nominal value. In-source fragmentation of the acyl glucuronide metabolite (compound III) did not interfere with the determination of parent compound I. The developed HTLC/MS/MS methodology was specific for compound I in the presence of compound III. Column life-time is increased and sample analysis time is decreased over traditional reversed-phase methods when direct injection assays for urine and dialysate are coupled with the technology of HTLC.
authors: Department of Drug Metabolism, Merck Research Laboratories, Merck & Co Inc, West Point, PA 19486-0004, USA. wei_zeng@merck.com
authors: Wei
authors: W
authors: Zeng
authors: Amy Qiu
authors: AQ
authors: Wang
authors: Alison L
authors: AL
authors: Fisher
authors: Donald G
authors: DG
authors: Musson
mesh_terms: D002851:Chromatography, High Pressure Liquid; D005561:Formates / Q000737:chemistry; D005615:Freezing; D020719:Glucuronides / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors*; D013058:Mass Spectrometry; D009287:Naphthyridines / Q000138:chemical synthesis* / Q000494:pharmacology*; D011786:Quality Control; D006435:Renal Dialysis; D013388:Succinimides / Q000138:chemical synthesis* / Q000494:pharmacology*
chemical_list: C480313:3-(2-oxo-3-(3-(5,6,7,8-tetrahydro(1,8)naphthyridin-2-yl)propyl)imidazolidin-1-yl)-3(s)-(6-methoxypyridin-3-yl)propionic acid; D005561:Formates; D020719:Glucuronides; D039302:Integrin alphaVbeta3; D009287:Naphthyridines; D013388:Succinimides; C030544:formic acid